This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singer, C. F. Articles by Cullen, K. J. Search for Related Content PubMed PubMed Citation Articles by Singer, C. F. Articles by Cullen, K. J.

Coexpression of Stromelysin-3 and Insulin-Like Growth Factor II in Tumors of Ectodermal, Mesodermal, and Endodermal Origin: Indicator of a Fetal Cell Phenotype¹

Vincent T. Lombardi Cancer Center, Georgetown University, Washington, D.C. 20007

Address all correspondence and requests for reprints to: Dr. Kevin J. Cullen, Division of Medical Oncology, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, D.C. 20007. E-mail: cullenk{at}gunet.georgetown.edu

Stromelysin-3 (ST-3) is thought to play an important role in invasion and tumor progression. We have analyzed ST-3 expression in fibroblasts with defined topographical relations to breast cancers. We demonstrate that these fibroblasts exhibit the same distinctive pattern of messenger ribonucleic acid (mRNA) expression that we have previously shown for insulin-like growth factor II (IGF-II). Tumor-derived fibroblasts and skin fibroblasts produce abundant ST-3 mRNA. Fibroblasts from normal breast stroma distant from the malignant tumor in the same patient express considerably less ST-3 mRNA. When we analyzed ST-3 and IGF-II gene expression in sarcomas, we found a similar pattern of coexpression. Immunohistochemical analysis of IGF-II and ST-3 protein expression in sarcomas and breast tumors confirmed the mRNA data.

ST-3 mRNA expression was also seen in most colon cancer cell lines, again matching reports of IGF-II gene expression. As the two proteins are known to play an important role during fetal growth and development, their coexpression in fibroblasts from malignant tumors of ectodermal (breast cancer) and mesodermal (sarcoma) origin and in epithelial cells of endodermal origin (colon cancer) implies a more primitive cellular phenotype. The regained ability to express such developmentally regulated proteins might, therefore, be a more general marker indicating a fetal-type phenotype of cells in a malignant tumor.

This article has been cited by other articles:

				A. Orimo, Y. Tomioka, Y. Shimizu, M. Sato, S. Oigawa, K. Kamata, Y. Nogi, S. Inoue, M. Takahashi, T. Hata, et al. Cancer-associated Myofibroblasts Possess Various Factors to Promote Endometrial Tumor Progression Clin. Cancer Res., October 1, 2001; 7(10): 3097 - 3105. [Abstract] [Full Text] [PDF]

				D. Luo, E. Guerin, M.-G. Ludwig, I. Stoll, P. Basset, and P. Anglard Transcriptional Induction of Stromelysin-3 in Mesodermal Cells Is Mediated by an Upstream CCAAT/Enhancer-binding Protein Element Associated with a DNase I-hypersensitive Site J. Biol. Chem., December 24, 1999; 274(52): 37177 - 37185. [Abstract] [Full Text] [PDF]

				F. Frasca, G. Pandini, P. Scalia, L. Sciacca, R. Mineo, A. Costantino, I. D. Goldfine, A. Belfiore, and R. Vigneri Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells Mol. Cell. Biol., May 1, 1999; 19(5): 3278 - 3288. [Abstract] [Full Text] [PDF]